|
CN105142672B
(zh)
*
|
2012-10-23 |
2019-04-05 |
西纳福克斯股份有限公司 |
经修饰的抗体、抗体-缀合物及其制备方法
|
|
JP6847388B2
(ja)
|
2013-03-15 |
2021-03-31 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
生物活性分子、そのコンジュゲート、及び治療用途
|
|
PL2991683T3
(pl)
*
|
2013-05-02 |
2020-03-31 |
Glykos Finland Oy |
Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
|
|
BR112016004023A2
(pt)
|
2013-08-26 |
2022-11-16 |
Regeneron Pharma |
Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
|
|
US9987373B2
(en)
|
2013-10-14 |
2018-06-05 |
Synaffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
WO2015057063A1
(en)
*
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
WO2015057066A1
(en)
*
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
EP3079668A1
(en)
|
2013-12-09 |
2016-10-19 |
Durect Corporation |
Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
|
|
US11168085B2
(en)
|
2014-01-24 |
2021-11-09 |
Synaffix B.V. |
Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne
|
|
US10266502B2
(en)
|
2014-01-24 |
2019-04-23 |
Synaffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
AU2015243512B2
(en)
|
2014-04-08 |
2020-06-04 |
University Of Georgia Research Foundation Inc. |
Site-specific antibody-drug glycoconjugates and methods
|
|
EP3160513B1
(en)
|
2014-06-30 |
2020-02-12 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
EP2974744A1
(en)
|
2014-07-16 |
2016-01-20 |
Stichting Katholieke Universiteit |
Strain-promoted oxidation controlled cycloaddition with high reaction rate
|
|
EP4148138A1
(en)
|
2014-08-04 |
2023-03-15 |
SynAffix B.V. |
Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
|
|
CN107106701B
(zh)
*
|
2014-10-03 |
2020-11-06 |
西纳福克斯股份有限公司 |
磺酰胺接头、其缀合物及制备方法
|
|
US10335495B2
(en)
*
|
2014-12-04 |
2019-07-02 |
Celgene Corporation |
Biomolecule conjugates
|
|
US20170369525A1
(en)
*
|
2014-12-31 |
2017-12-28 |
Development Center For Biotechnology |
Site-specific conjugation through glycoproteins linkage and method thereof
|
|
US11559581B2
(en)
*
|
2015-01-09 |
2023-01-24 |
Oxford University Innovation Limited |
Antibody conjugates and methods of making the antibody conjugates
|
|
BR112017020149A8
(pt)
|
2015-03-27 |
2023-05-02 |
Regeneron Pharma |
Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
|
|
WO2016170186A1
(en)
|
2015-04-23 |
2016-10-27 |
Synaffix B.V. |
PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE
|
|
WO2016172615A1
(en)
*
|
2015-04-24 |
2016-10-27 |
University Of Delaware |
Synthetic n-acetyl-muramic acid derivatives and uses thereof
|
|
IL296285A
(en)
|
2015-07-06 |
2022-11-01 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
CA2995145C
(en)
*
|
2015-08-26 |
2023-08-01 |
Vib Vzw |
Means and methods for monitoring inflammation
|
|
KR20180058737A
(ko)
*
|
2015-10-07 |
2018-06-01 |
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 |
암 선택적 표지화 및 표적화를 위한 트리거-활성화 대사성 당 전구체
|
|
CN107029242A
(zh)
|
2015-11-03 |
2017-08-11 |
财团法人工业技术研究院 |
抗体药物复合物及其制造方法
|
|
MA43416A
(fr)
|
2015-12-11 |
2018-10-17 |
Regeneron Pharma |
Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
|
|
BR112018014759B1
(pt)
|
2016-01-25 |
2024-02-27 |
Regeneron Pharmaceuticals, Inc |
Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
|
|
CN108495653A
(zh)
*
|
2016-01-27 |
2018-09-04 |
免疫医疗有限责任公司 |
用于制备具有定义的糖基化模式抗体的方法
|
|
JP2017200902A
(ja)
*
|
2016-02-08 |
2017-11-09 |
シンアフィックス ビー．ブイ． |
Ｈｅｒ２腫瘍を標的化するための改善された治療指数を有する新規な抗体−コンジュゲート及び抗体−コンジュゲートの治療指数を改善するための方法
|
|
JP2017197512A
(ja)
*
|
2016-02-08 |
2017-11-02 |
シンアフィックス ビー．ブイ． |
Ｃｄ３０腫瘍を標的化するための改善された治療指数を有する新規な抗体−コンジュゲート及び抗体−コンジュゲートの治療指数を改善するための方法
|
|
ES2972511T3
(es)
|
2016-02-08 |
2024-06-13 |
Synaffix Bv |
Enzimas para el corte de glicoproteínas
|
|
EP3413920A1
(en)
|
2016-02-08 |
2018-12-19 |
Synaffix B.V. |
Bioconjugates containing sulfamide linkers for use in treatment
|
|
EP3413915A1
(en)
*
|
2016-02-08 |
2018-12-19 |
Synaffix B.V. |
Antibody-conjugates with improved therapeutic index for targeting her2 tumours and method for improving therapeutic index of antibody-conjugates
|
|
WO2017137457A1
(en)
|
2016-02-08 |
2017-08-17 |
Synaffix B.V. |
Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
|
|
US10874746B2
(en)
|
2016-02-08 |
2020-12-29 |
Synaffix B.V. |
Sulfamide linkers for use in bioconjugates
|
|
WO2017137458A1
(en)
|
2016-02-08 |
2017-08-17 |
Synaffix B.V. |
Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
|
|
PE20231050A1
(es)
|
2016-03-02 |
2023-07-11 |
Eisai Randd Man Co Ltd |
Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
|
|
EP3448891A1
(en)
|
2016-04-28 |
2019-03-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
JP7020403B2
(ja)
*
|
2016-05-02 |
2022-02-16 |
味の素株式会社 |
アジド基含有Ｆｃタンパク質
|
|
WO2017218891A1
(en)
*
|
2016-06-17 |
2017-12-21 |
Life Technologies Corporation |
Site-specific crosslinking of antibodies
|
|
JP7128121B2
(ja)
|
2016-06-28 |
2022-08-30 |
ヴェンタナ メディカル システムズ， インク． |
Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
|
|
WO2018003983A1
(ja)
*
|
2016-07-01 |
2018-01-04 |
第一三共株式会社 |
ｈＡＮＰ－Ｆｃ含有分子コンジュゲート
|
|
EP3478324A1
(en)
|
2016-07-01 |
2019-05-08 |
GlaxoSmithKline Intellectual Property (No.2) Limited |
Antibody-drug conjugates and therapeutic methods using the same
|
|
MY199468A
(en)
*
|
2016-09-23 |
2023-10-31 |
Regeneron Pharma |
Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
|
|
US10738338B2
(en)
|
2016-10-18 |
2020-08-11 |
The Research Foundation for the State University |
Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
|
|
ES3046537T3
(en)
|
2016-11-08 |
2025-12-02 |
Regeneron Pharma |
Steroids and protein-conjugates thereof
|
|
EP3538098A4
(en)
*
|
2016-11-14 |
2020-07-29 |
Cho Pharma Inc |
ANTIBODY-DRUG CONJUGATES
|
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
|
|
CN110121365A
(zh)
|
2016-12-29 |
2019-08-13 |
财团法人生物技术开发中心 |
制备糖蛋白-药物偶联物的方法
|
|
EP3577138A1
(en)
|
2017-02-06 |
2019-12-11 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
|
US11299509B2
(en)
|
2017-02-10 |
2022-04-12 |
The Board Of Trustees Of The University Of Illinois |
Trigger-activatable sugar conjugates for cancer-selective labeling and targeting
|
|
KR20200005635A
(ko)
|
2017-05-11 |
2020-01-15 |
브이아이비 브이지더블유 |
가변 면역글로불린 도메인의 글리코실화
|
|
KR20200007905A
(ko)
|
2017-05-18 |
2020-01-22 |
리제너론 파마슈티칼스 인코포레이티드 |
사이클로덱스트린 단백질 약물 접합체
|
|
WO2018213082A1
(en)
|
2017-05-18 |
2018-11-22 |
Regeneron Pharmaceuticals, Inc. |
Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
|
|
DK3635009T3
(da)
|
2017-06-07 |
2026-03-30 |
Regeneron Pharma |
Sammensætninger og fremgangsmåder til internalisering af enzymer
|
|
CA3072399A1
(en)
|
2017-08-09 |
2019-02-14 |
Helmholtz-Zentrum Fur Infektionsforschung Gmbh |
New targeted cytotoxic ratjadone derivatives and conjugates thereof
|
|
EP3441766B1
(en)
*
|
2017-08-11 |
2020-03-11 |
Life Science Inkubator Sachsen GmbH & Co. KG |
Novel antibody conjugates suitable for use in discrete fluorescence quenching displacement immunoassays
|
|
NZ762505A
(en)
|
2017-09-29 |
2026-03-27 |
Daiichi Sankyo Co Ltd |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
MX2020004691A
(es)
|
2017-11-07 |
2020-08-20 |
Regeneron Pharma |
Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
|
|
CN111727075B
(zh)
|
2017-11-27 |
2024-04-05 |
普渡制药公司 |
靶向人组织因子的人源化抗体
|
|
EP3720504A1
(en)
*
|
2017-12-06 |
2020-10-14 |
Synaffix B.V. |
Enediyne conjugates
|
|
KR20200104889A
(ko)
|
2017-12-29 |
2020-09-04 |
글리코미메틱스, 인크. |
E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
|
|
SG11202006510XA
(en)
|
2018-01-08 |
2020-08-28 |
Regeneron Pharma |
Steroids and antibody-conjugates thereof
|
|
KR102871690B1
(ko)
|
2018-04-30 |
2025-10-16 |
리제너론 파마슈티칼스 인코포레이티드 |
Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
|
|
CN118955710A
(zh)
|
2018-05-09 |
2024-11-15 |
里珍纳龙药品有限公司 |
抗msr1抗体及其使用方法
|
|
BR112020023145A2
(pt)
|
2018-05-17 |
2021-02-02 |
Regeneron Pharmaceuticals, Inc. |
anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
|
|
JP2019206491A
(ja)
*
|
2018-05-29 |
2019-12-05 |
国立研究開発法人理化学研究所 |
乳がんまたは胃がんの治療のための抗体−薬物複合体
|
|
JP7273858B2
(ja)
*
|
2018-06-15 |
2023-05-15 |
シャンハイ ミラコーケン インコーポレイティド |
癌を治療するための方法と材料
|
|
AU2019314538B2
(en)
*
|
2018-08-02 |
2025-03-13 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11911484B2
(en)
*
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
IL280536B2
(en)
*
|
2018-08-02 |
2024-12-01 |
Dyne Therapeutics Inc |
Complexes targeting transferrin receptor and uses thereof
|
|
CA3108282A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
SG11202100928QA
(en)
|
2018-08-02 |
2021-02-25 |
Dyne Therapeutics Inc |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US12097263B2
(en)
*
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
CN113260384A
(zh)
*
|
2018-11-05 |
2021-08-13 |
西纳福克斯股份有限公司 |
用于靶向表达trop-2的肿瘤的抗体缀合物
|
|
IL283313B2
(en)
|
2018-11-20 |
2025-08-01 |
Regeneron Pharma |
Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
|
|
JP7590328B2
(ja)
|
2018-12-21 |
2024-11-26 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
ツブリシン及びタンパク質－ツブリシンコンジュゲート
|
|
PH12021551476A1
(en)
|
2018-12-21 |
2022-04-25 |
Regeneron Pharma |
Rifamycin analogs and antibody-drug conjugates thereof
|
|
US11845771B2
(en)
|
2018-12-27 |
2023-12-19 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectin and galectin-3
|
|
CA3122321A1
(en)
|
2018-12-27 |
2020-07-02 |
Glycomimetics, Inc. |
Galectin-3 inhibiting c-glycosides
|
|
BR112021013464A2
(pt)
|
2019-01-08 |
2021-09-21 |
Regeneron Pharmaceuticals, Inc. |
Ligantes sem traço e conjugados de proteína dos mesmos
|
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
|
CA3128519A1
(en)
|
2019-02-21 |
2020-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
|
|
WO2020196475A1
(ja)
*
|
2019-03-25 |
2020-10-01 |
第一三共株式会社 |
抗ｈｅｒ２抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
|
|
CN113631229B
(zh)
*
|
2019-03-25 |
2025-09-23 |
第一三共株式会社 |
抗体－吡咯并苯并二氮杂卓衍生物偶联物
|
|
CA3139180A1
(en)
*
|
2019-03-27 |
2020-10-01 |
Daiichi Sankyo Company, Limited |
Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
|
|
EP3976112A1
(en)
|
2019-06-03 |
2022-04-06 |
Synaffix B.V. |
Acetal-based cleavable linkers
|
|
AU2020349462A1
(en)
|
2019-09-16 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled MET binding proteins for immuno-PET imaging
|
|
US11814428B2
(en)
|
2019-09-19 |
2023-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-PTCRA antibody-drug conjugates and uses thereof
|
|
EP3828196A4
(en)
*
|
2019-09-29 |
2022-04-27 |
MabPlex International Co., Ltd. |
METHOD FOR PREPARING AN INTERMEDIATE ANTIBODY-DRUG CONJUGATE BY ACID METHOD AND APPLICATION THEREOF
|
|
GB201917388D0
(en)
*
|
2019-11-28 |
2020-01-15 |
Cambridge Entpr Ltd |
Novel linker compounds
|
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
|
BR112022013255A2
(pt)
*
|
2020-01-09 |
2022-09-06 |
Mersana Therapeutics Inc |
Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo
|
|
CN115666656A
(zh)
|
2020-01-13 |
2023-01-31 |
西纳福克斯股份有限公司 |
通过环加成双侧功能化抗体
|
|
JP7807375B2
(ja)
|
2020-01-13 |
2026-01-27 |
シンアフィックス ビー．ブイ． |
付加環化を介して両側官能化された抗体
|
|
WO2021144315A1
(en)
|
2020-01-13 |
2021-07-22 |
Synaffix B.V. |
Conjugates of antibodies an immune cell engagers
|
|
JP2023511956A
(ja)
|
2020-01-24 |
2023-03-23 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
タンパク質－抗ウイルス化合物コンジュゲート
|
|
KR20220148200A
(ko)
|
2020-02-28 |
2022-11-04 |
리제너론 파마슈티칼스 인코포레이티드 |
Her2에 결합하는 이중특이적 항원 결합 분자 및 이의 사용 방법
|
|
CN115968304A
(zh)
|
2020-04-16 |
2023-04-14 |
瑞泽恩制药公司 |
狄尔斯-阿尔德缀合方法
|
|
KR20230012539A
(ko)
|
2020-05-13 |
2023-01-26 |
디스크 메디슨, 인크. |
골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
|
|
US20230183347A1
(en)
|
2020-05-25 |
2023-06-15 |
Foundation For Biomedical Research And Innovation At Kobe |
PD-1 Agonist-Containing Pharmaceutical Composition for Treating or PReventing TH2-Mediated Disease
|
|
CN111560078A
(zh)
*
|
2020-06-19 |
2020-08-21 |
联宁（苏州）生物制药有限公司 |
具有马来酰亚胺接头的双臂中间体及其合成方法
|
|
WO2021262910A2
(en)
|
2020-06-24 |
2021-12-30 |
Regeneron Pharmaceuticals, Inc. |
Tubulysins and protein-tubulysin conjugates
|
|
EP4172141A1
(en)
|
2020-06-26 |
2023-05-03 |
Synaffix B.V. |
Methods for the preparation of linker payload constructs
|
|
CN116390771A
(zh)
|
2020-07-13 |
2023-07-04 |
瑞泽恩制药公司 |
与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途
|
|
NL2026400B1
(en)
|
2020-09-02 |
2022-05-04 |
Synaffix Bv |
Methods for the preparation of bioconjugates
|
|
CA3191304A1
(en)
|
2020-09-14 |
2022-03-17 |
Amy Han |
Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
|
|
JP2023541637A
(ja)
|
2020-09-15 |
2023-10-03 |
シンアフィックス ビー．ブイ． |
抗体－エクサテカンコンジュゲート
|
|
WO2022081895A1
(en)
|
2020-10-16 |
2022-04-21 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
CA3190569A1
(en)
|
2020-10-22 |
2022-04-28 |
Christopher Daly |
Anti-fgfr2 antibodies and methods of use thereof
|
|
NL2026947B1
(en)
|
2020-11-20 |
2022-07-01 |
Synaffix Bv |
Tyrosine-based antibody conjugates
|
|
EP4267195A1
(en)
|
2020-12-24 |
2023-11-01 |
Synaffix B.V. |
Glycan-conjugated antibodies binding to fc-gamma receptor
|
|
CA3202832A1
(en)
|
2020-12-31 |
2022-07-07 |
Romesh R. Subramanian |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
JP2024506022A
(ja)
|
2021-02-08 |
2024-02-08 |
シンアフィックス ビー．ブイ． |
多機能性抗体
|
|
US20240209080A1
(en)
|
2021-04-10 |
2024-06-27 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
JP2024525608A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体および製剤
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
CA3220081A1
(en)
|
2021-07-28 |
2023-02-02 |
Thomas Nittoli |
Protein-antiviral compound conjugates
|
|
US20240350658A1
(en)
*
|
2021-10-20 |
2024-10-24 |
Glyco-Therapy Biotechnology Co., Ltd. |
Site-specific glycoprotein conjugates and methods for making the same
|
|
KR102782629B1
(ko)
*
|
2021-11-12 |
2025-03-19 |
닥터아이앤비(주) |
생산 시간을 단축하고 안정성이 개선된 의약품 제조방법
|
|
JP2024540480A
(ja)
|
2021-11-17 |
2024-10-31 |
ディスク・メディシン・インコーポレイテッド |
腎臓疾患の貧血を処置する方法
|
|
US20230414775A1
(en)
|
2021-12-29 |
2023-12-28 |
Regeneron Pharmaceuticals, Inc. |
Tubulysins and protein-tubulysin conjugates
|
|
CA3241734A1
(en)
|
2022-01-12 |
2023-07-20 |
Amy Han |
Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
|
|
AU2023208050A1
(en)
|
2022-01-14 |
2024-07-04 |
Regeneron Pharmaceuticals, Inc. |
Verrucarin a derivatives and antibody drug conjugates thereof
|
|
WO2023141855A1
(en)
*
|
2022-01-27 |
2023-08-03 |
Glyco-Therapy Biotechnology Co., Ltd. |
Protein conjugates with multiple payloads and methods for making the same
|
|
JP2025505835A
(ja)
*
|
2022-02-22 |
2025-02-28 |
アーデーセー セラピューティクス ソシエテ アノニム |
トリミングされたｎ－グリカンを含むｆｃ領域でのトランスグルタミナーゼを伴うコンジュゲーション方法
|
|
JP2025512735A
(ja)
|
2022-03-11 |
2025-04-22 |
リジェネロン ファーマシューティカルズ，インク． |
Ｇｌｐ１ペプチド模倣体を含む抗ｇｌｐ１ｒ抗体係留型薬物コンジュゲートおよびその使用
|
|
US20250205353A1
(en)
|
2022-03-23 |
2025-06-26 |
Synaffix B.V. |
Antibody-conjugates for targeting of tumours expressing nectin-4
|
|
CA3253220A1
(en)
|
2022-03-23 |
2023-09-28 |
Synaffix B.V. |
ANTIBODIES CONJUGATED FOR TARGETING TUMORS EXPRESSING TROP-2
|
|
KR20250024741A
(ko)
|
2022-03-23 |
2025-02-19 |
시나픽스 비.브이. |
암배아성 항원을 발현하는 종양을 표적화하기 위한 항체-컨쥬게이트
|
|
IL315366A
(en)
|
2022-03-23 |
2024-11-01 |
Synaffix Bv |
Antibody pairs for targeting PTK7-expressing tumors
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
EP4285934A1
(en)
|
2022-05-30 |
2023-12-06 |
CER Groupe |
Modified trimannose-oligosacharides, bisected n-glycans comprising said trimannose core and method for obtaining them
|
|
CN120239705A
(zh)
|
2022-07-21 |
2025-07-01 |
萤火虫生物股份有限公司 |
糖皮质激素受体激动剂和其缀合物
|
|
CN119997985A
(zh)
|
2022-08-15 |
2025-05-13 |
西纳福克斯股份有限公司 |
蒽环类药物及其缀合物
|
|
EP4344707A1
(en)
|
2022-09-29 |
2024-04-03 |
Emergence Therapeutics AG |
New anti-nectin-4 antibody drug conjugates
|
|
WO2024118785A2
(en)
|
2022-11-30 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Tlr7 agonists and antibody-drug-conjugates thereof
|
|
WO2024121123A1
(en)
|
2022-12-06 |
2024-06-13 |
Synaffix B.V. |
Synthesis of endo-bicyclononene
|
|
WO2024138000A1
(en)
|
2022-12-21 |
2024-06-27 |
Regeneron Pharmaceuticals, Inc. |
Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
|
|
JP2026504737A
(ja)
*
|
2022-12-22 |
2026-02-09 |
ヤンセン ファーマシューティカ エヌ．ベー． |
抗体－ポリヌクレオチドコンジュゲートを調製する方法
|
|
EP4389152A1
(en)
|
2022-12-23 |
2024-06-26 |
Synaffix B.V. |
Conjugates of pbd prodrugs
|
|
WO2024150074A2
(en)
|
2023-01-13 |
2024-07-18 |
Takeda Pharmaceutical Company Limited |
Coronavirus antibodies and therapeutic uses thereof
|
|
EP4653020A1
(en)
|
2023-01-19 |
2025-11-26 |
Shanghai Shengdi Pharmaceutical Co., Ltd |
Tyrosinase-mediated protein site-specific conjugation and use thereof
|
|
EP4410313A1
(en)
|
2023-01-31 |
2024-08-07 |
Synaffix B.V. |
Homogeneous antibody-conjugates with high payload loading
|
|
WO2024168199A1
(en)
|
2023-02-09 |
2024-08-15 |
Regeneron Pharmaceuticals, Inc. |
Antibody-drug conjugates via inverse electron demand diels-alder reactions
|
|
KR20250158054A
(ko)
|
2023-03-02 |
2025-11-05 |
알로이 테라퓨틱스, 인크. |
항-cd22 항체 및 이의 용도
|
|
WO2024199432A1
(en)
*
|
2023-03-30 |
2024-10-03 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Site-speicfic orthogonal bioconjugate modality and application thereof
|
|
WO2024199442A1
(en)
*
|
2023-03-30 |
2024-10-03 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Disaccharide linker, linker-payload containing the same and glycan chain-remodeled antibody-drug conjugate, preparation method and uses thereof
|
|
WO2024218164A1
(en)
|
2023-04-17 |
2024-10-24 |
Synaffix B.V. |
Stable 4-isoxazoline conjugates
|
|
EP4450489A1
(en)
|
2023-04-18 |
2024-10-23 |
Synaffix B.V. |
Stable 4-isoxazoline conjugates
|
|
EP4450093A1
(en)
|
2023-04-17 |
2024-10-23 |
Synaffix B.V. |
Cleavable immune cell engagers
|
|
WO2024229105A1
(en)
|
2023-05-02 |
2024-11-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
|
|
KR20260008776A
(ko)
|
2023-05-08 |
2026-01-16 |
사노피 |
면역글로불린 단일 가변 도메인의 글리코실화
|
|
EP4719482A1
(en)
|
2023-06-05 |
2026-04-08 |
Vib Vzw |
Glyco-engineered antibody-drug-conjugates comprising an oxime linker
|
|
KR20260039735A
(ko)
*
|
2023-07-10 |
2026-03-20 |
수리오 테라퓨틱스 컴퍼니 리미티드 |
기능화된 아우리스타틴, 약제학적 조성물, 및 치료적 적용
|
|
CN121568720A
(zh)
|
2023-07-10 |
2026-02-24 |
瑞泽恩制药公司 |
抗人类cacng1抗体-药物缀合物及其用途
|
|
AU2024299328A1
(en)
|
2023-07-21 |
2026-01-22 |
Marrow Therapeutics, Inc. |
Hematopoietic cell targeting conjugates and related methods
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
EP4541376A1
(en)
|
2023-10-17 |
2025-04-23 |
ADC Therapeutics SA |
Antibody-drug conjugates
|
|
US20250171516A1
(en)
|
2023-11-03 |
2025-05-29 |
Regeneron Pharmaceuticals, Inc. |
Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
|
|
WO2025117727A1
(en)
|
2023-11-29 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
|
|
TW202530255A
(zh)
|
2023-12-15 |
2025-08-01 |
法商亞維西亞有限公司 |
抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
|
|
EP4574174A1
(en)
|
2023-12-19 |
2025-06-25 |
Jack Elands |
Novel antibody-drug conjugates comprising an anti-(tcr)-cd3-complex binding antibody
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025163120A1
(en)
|
2024-02-01 |
2025-08-07 |
Adcytherix Sas |
ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY
|
|
WO2025172468A1
(en)
|
2024-02-13 |
2025-08-21 |
Synaffix B.V. |
Method for producing azido-sugars and compounds obtained thereby
|
|
US20250381289A1
(en)
|
2024-02-29 |
2025-12-18 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025238253A1
(en)
|
2024-05-16 |
2025-11-20 |
Synaffix B.V. |
Antibody-oligonucleotide conjugates
|
|
WO2025262641A1
(en)
|
2024-06-19 |
2025-12-26 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
|
WO2026006494A1
(en)
|
2024-06-25 |
2026-01-02 |
Alloy Therapeutics, Inc. |
Anti-cd3 antibodies and uses thereof
|
|
WO2026006495A1
(en)
|
2024-06-25 |
2026-01-02 |
Alloy Therapeutics, Inc. |
Anti-wt1/hla-a2 antibody and uses thereof
|
|
WO2026006492A2
(en)
|
2024-06-25 |
2026-01-02 |
Ypsilon Therapeutics, Inc. |
Anti-prame/hla-a2 antibodies and uses thereof
|
|
WO2026008881A1
(en)
|
2024-07-05 |
2026-01-08 |
Synaffix B.V. |
Extracellular vesicles comprising biomolecule-conjugates
|
|
US20260078179A1
(en)
|
2024-07-18 |
2026-03-19 |
Novarock Biotherapeutics, Ltd. |
Cdh17 antibodies and uses thereof
|
|
WO2026035986A1
(en)
|
2024-08-07 |
2026-02-12 |
Bighat Biosciences, Inc. |
Humanized anti-cdh17 antibodies and use of the same
|
|
US20260048137A1
(en)
|
2024-08-16 |
2026-02-19 |
Ardeagen Corporation |
Anti-mesothelin antibody conjugates and methods of use thereof
|
|
WO2026052513A1
(en)
|
2024-09-09 |
2026-03-12 |
Adcytherix Sas |
Antibody-drug conjugates comprising an flt3 binding antibody
|